Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) – Pipeline Review, H2 2017’, provides in depth analysis on Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Gastrointestinal, Oncology, Respiratory, Dermatology, Genetic Disorders, Genito Urinary System And Sex Hormones, Immunology, Metabolic Disorders, Ophthalmology, Cardiovascular and Musculoskeletal Disorders under development targeting Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF)

The report reviews Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) targeted therapeutics and enlists all their major and minor projects

The report assesses Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

BLR Bio LLC

FibroGen Inc

ProMetic Life Sciences Inc

RXi Pharmaceuticals Corp

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) - Overview

Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) - Companies Involved in Therapeutics Development

BLR Bio LLC

FibroGen Inc

ProMetic Life Sciences Inc

RXi Pharmaceuticals Corp

Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) - Drug Profiles

BLR-100 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BLR-200 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BLR-300 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BLR-400 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IB-DMD - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OLX-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OLX-201 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OLX-701 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pamrevlumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PBI-4050 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RXI-109 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) - Dormant Products

Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) - Discontinued Products

Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) - Product Development Milestones

Featured News & Press Releases

Sep 25, 2017: Prometic receives FDA clearance of its IND to initiate pivotal PBI-4050 Phase 2/3 trial in patients with idiopathic pulmonary fibrosis

Sep 19, 2017: Prometic Reports Positive Clinical Data from Ongoing PBI-4050 Study in Alstrom Syndrome Patients

Sep 13, 2017: Fibrogen Presents Latest Data From Phase 2b Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis at European Respiratory Society International Congress 2017

Sep 05, 2017: FibroGen Announces Pamrevlumab Oral and Poster Presentations at European Respiratory Society International Congress 2017

Aug 07, 2017: FibroGen Announces Positive Topline Results from Phase 2 Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis

Jun 21, 2017: FibroGen Granted Orphan Drug Designation for Pamrevlumab in the Treatment of Pancreatic Cancer

Jun 21, 2017: RXi Pharmaceuticals Announces Completion of Enrollment of Phase 1/2 Clinical Trial with RXI-109 for Retinal Scarring

Jun 12, 2017: New data presented by Prometic at ADA's Scientific Sessions validates PBI-4050's positive impact on kidneys in patients with diabetes and metabolic syndrome

May 23, 2017: Prometic Presents New Data on PBI-4050 and Plasminogen at the American Thoracic Societys 2017 International Conference

May 08, 2017: Prometic to Present New Data on PBI-4050 at the American Thoracic Society's 2017 International Conference

May 02, 2017: RXi Pharmaceuticals to Present at the Association for Research in Vision and Ophthalmology 2017 Annual Meeting

Apr 20, 2017: Prometics PBI-4050 Shown To Reduce Liver Damage And Fibrosis In High-fat Diet Induced Obesity And Metabolic Syndrome Mouse Model

Apr 18, 2017: FDA Confirms Prometic's PBI-4050 IPF Clinical Trial Design

Mar 28, 2017: RXi Pharmaceuticals Granted Patent in Japan for Lead Clinical Candidate RXI-109

Mar 03, 2017: US FDA Grants Orphan Drug Designation to Prometic's PBI-4050 Drug for the Treatment of Alstrom Syndrome

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Indications, H2 2017

Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Pipeline by BLR Bio LLC, H2 2017

Pipeline by FibroGen Inc, H2 2017

Pipeline by ProMetic Life Sciences Inc, H2 2017

Pipeline by RXi Pharmaceuticals Corp, H2 2017

Dormant Projects, H2 2017

Discontinued Products, H2 2017

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Top 10 Indications, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports